Catalent, Inc. Appoints Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer
09 Februar 2015 - 10:06PM
Business Wire
Catalent, Inc. (NYSE:CTLT), the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced that it has
appointed Thomas Castellano as Vice President Finance, Investor
Relations, and Treasurer effective immediately.
Mr. Castellano joined Catalent in 2008 when the Company formed
its Financial Planning and Analysis (FP&A) group and was
actively involved in building out its financial operations. His
role at Catalent expanded in December 2014, when he was named
Treasurer of the Company.
“We are very pleased that Tom will now lead our investor
relations efforts,” said John Chiminski, President and Chief
Executive Officer of Catalent, Inc. “During his years with
Catalent, he has played a critical role in the Company’s
transformational journey and in our July 2014 initial public
offering. His expertise in financial leadership and capital
markets, as well as his profound knowledge of Catalent’s
operations, will be invaluable in building relationships with Wall
Street and our shareholders.”
Prior to joining Catalent, Mr. Castellano worked with the
Capital Markets Finance group at Lehman Brothers, where he held
roles of increasing responsibility. He began his career at Cendant
Corporation as part of its Financial Leadership Development Program
and was later promoted into the FP&A group of its Real Estate
Division. While at Cendant, he participated in the successful
spin-off of Realogy Holdings Corporation in 2006.
“Catalent has a very compelling and diverse portfolio of
technologies and products. I look forward to communicating our
story to investors and analysts as we continue to execute on our
business strategy and expand our market share,” commented Mr.
Castellano.
Mr. Castellano holds a BS in Finance and an MBA with an emphasis
in Finance, both from Seton Hall University.
In addition to leading the Investor Relations function, Mr.
Castellano will continue to oversee Catalent’s FP&A group and
remain Treasurer of the Company.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products. With over 80 years serving
the industry, Catalent has proven expertise in bringing more
customer products to market faster, enhancing product performance
and ensuring reliable clinical and commercial product supply.
Catalent employs approximately 8,000 people, including over 1,000
scientists, at nearly 30 facilities across 5 continents and in
fiscal 2014 generated more than $1.8 billion in annual revenue.
Catalent is headquartered in Somerset, N.J. For more information,
please visit www.catalent.com.
Forward-Looking Statements
This release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,”
“likely,” “may,” “will,” “would” or other words or phrases with
similar meanings. Similarly, statements that describe our
objectives, plans or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent, Inc.’s expectations and projections.
Some of the factors that could cause actual results to differ
include, but are not limited to, the following: participation in a
highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s
offerings which depends in part on the Company’s customers’
research and development and the clinical and market success of
their products; product and other liability risks that could
adversely affect the Company’s results of operations, financial
condition, liquidity and cash flows; failure to comply with
existing and future regulatory requirements; failure to provide
quality offerings to customers could have an adverse effect on our
business and subject the Company to regulatory actions and costly
litigation; problems providing the highly exacting and complex
services or support required; global economic, political and
regulatory risks to the operations of the Company; inability to
enhance existing or introduce new technology or service offerings
in a timely manner; inadequate patents, copyrights, trademarks and
other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials;
changes in market access or healthcare reimbursement in the United
States or internationally; fluctuations in the exchange rate of the
U.S. dollar and other foreign currencies; adverse tax legislation
initiatives or challenges to the Company’s tax positions; loss of
key personnel; risks generally associated with information systems;
inability to complete any future acquisitions and other
transactions that may complement or expand the business of the
Company or divest of non-strategic businesses or assets and the
Company’s ability to successfully integrate acquired business and
realize anticipated benefits of such acquisitions; offerings and
customers’ products that may infringe on the intellectual property
rights of third parties; environmental, health and safety laws and
regulations, which could increase costs and restrict operations;
labor and employment laws and regulations; additional cash
contributions required to fund the Company’s existing pension
plans; substantial leverage resulting in the limited ability of the
Company to raise additional capital to fund operations and react to
changes in the economy or in the industry, exposure to interest
rate risk to the extent of the Company’s variable rate debt and
preventing the Company from meeting our obligations under our
indebtedness. For a more detailed discussion of these and other
factors, see the information under the caption “Risk Factors” in
our 10-K for the fiscal year ended June 30, 2014, filed with the
Securities and Exchange Commission. All forward-looking statements
speak only as of the date of this release or as of the date they
are made, and Catalent, Inc. does not undertake to update any
forward-looking statement as a result of new information or future
events or developments except to the extent required by law.
More products. Better treatments. Reliably supplied.™
Investors:Catalent, Inc.Thomas Castellano,
732-537-6325investors@catalent.comorBertner AdvisorsJeremy Feffer,
732-537-6325investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024